Personalized Medicine2019-06-28T07:53:15+00:00
SCIENCE

Personalized Medicine

SCIENCE

Personalized
Medicine

Personalized Molecular Medicine® is use of genomics and patient specific information to identify optimal treatment for each patient.

Mutations in genomic DNA drive normal cells to become cancerous. Since each cancer has a distinct genetic fingerprint, biomarker testing allows us to identify mutations so physicians can match targeted drugs and treatments to the mutations responsible for driving cancer. This helps you achieve the best possible clinical outcome.

Personalized Molecular Medicine® is use of genomics and patient specific information to identify optimal treatment for each patient.

Mutations in genomic DNA drive normal cells to become cancerous. Since each cancer has a distinct genetic fingerprint, biomarker testing allows us to identify mutations so physicians can match targeted drugs and treatments to the mutations responsible for driving cancer. This helps you achieve the best possible clinical outcome.

PATIENT INFORMATION

Why it Matters

Targeted drugs and combination therapies can drive cancer into remission, as they achieve optimal results in subsets of patients.

Molecular diagnostic tests identify mutations that can be targeted by drugs to optimize individual patient’s treatment. Biomarker testing is used more frequently to identify targeted therapies, monitor patients, and aid in treatment decisions. This strategy is becoming a Standard of Care in hematology/oncology more than in any other field of medicine.

TECHNICAL INFORMATION

How it Works

Targeted drugs bind and shut down the activity of key aberrant proteins that drive proliferation of cancer cells.

Targeted drugs bind and shut down the activity of aberrant proteins – products of specific mutations. Patients who lack these mutations are less likely to benefit from these drugs. Fast, relatively inexpensive genetic tests can quickly inform the patient and their physician which treatments have the best chance for success.

PATIENT INFORMATION

Why it Matters

Targeted drugs and combination therapies can drive cancer into remission, as they achieve optimal results in subsets of patients.

Molecular diagnostic tests identify mutations that can be targeted by drugs to optimize individual patient’s treatment. Biomarker testing is used more frequently to identify targeted therapies, monitor patients, and aid in treatment decisions. This strategy is becoming a Standard of Care in hematology/oncology more than in any other field of medicine.

TECHNICAL INFORMATION

How it Works

Targeted drugs bind and shut down the activity of key aberrant proteins that drive proliferation of cancer cells.

Targeted drugs bind and shut down the activity of aberrant proteins – products of specific mutations. Patients who lack these mutations are less likely to benefit from these drugs. Fast, relatively inexpensive genetic tests can quickly inform the patient and their physician which treatments have the best chance for success.